Formation of mixed platelet-PMN leukocyte aggregates in the platelet function analyzer (PFA-100) device

 

^* Present address: Clinical Cardiovascular Biology Research Centre, Cardio-Thoracic and VascularDepartment, University Vita-Salute San Raffaele, Milan, Italy.

• References

• 1 de Gaetano G, Cerletti C. Platelet adhesion and aggregation and fibrin formation in flowing blood: a historical contribution by Giulio Bizzozero. Platelets 2002; 13: 85-9.
• 2 Rinder HM, Bonan JL, Rinder CS. et al Dynamics of leukocyte-platelet adhesion in whole blood. Blood 1991; 78: 1730-7.
• 3 Palabrica T, Lobb R, Furie BC. et al Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-51.
• 4 Evangelista V, Manarini S, Rotondo S. et al Platelet/ polymorphonuclear leukocyte interaction in dynamic conditions: evidence of adhesion cascade and cross talk between P-selectin and ? 2 integrin CD11b/CD18. Blood 1996; 88: 4183-94.
• 5 Kirchhofer D, Riederer MA, Baumgartner HR. Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model. Blood 1997; 89: 1270-8.
• 6 Cerletti C, Evangelista V, de Gaetano G. P-selectin-? 2 integrin cross-talk: a molecular mechanism for polymorphonuclear leukocyte recruitment at the site of vascular damage. Thromb Haemost 1999; 82: 787-93.
• 7 Maugeri N, Santarelli MT, Lazzari MA. Circulating platelet-polymorphonuclear leukocyte aggregates in patients with heart valve replacement. Am J Hematol 2000; 65: 93-8.
• 8 de Gaetano G, Donati MB, Cerletti C. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. Trends Pharmacol Sci 2003; 24: 245-52.
• 9 Martins Pda C, Zwaginga JJ. Leukocyte-platelet aggregates: new particles reflecting and effecting cardiovascular disease. Thromb Haemost 2005; 94: 1120-1.
• 10 Maugeri N, de Gaetano G, Barbanti M. et al Prevention of platelet-polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, a low molecular weight heparin. Haematologica 2005; 90: 833-9.
• 11 Hayward CP, Harrison P, Cattaneo M. et al The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 312-9.
• 12 Packham AM, Rand ML, Kinlough-Rathbone RL.. Aggregation. In Platelets in thrombotic and non thrombotic disorders. Cambridge University Press; 2002. pp 338-356.
• 13 Maugeri N, Giordano G, Petrilli MP. et al Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?. J Thromb Haemost 2006; 4: 2593-8.
• 14 Wang L, Brown JR, Varki A. et al Heparin’s anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L-and P-selectins. J Clin Invest 2002; 110: 127-36.